CD8+ cells, NK1.1+ cells and IFN-γ contributed to the anti-tumor effect of both ODN1826 and α-GalCer but MΦs reduced tumor growth only after administration of ODN1826 and this adjuvant stimulated also immunosuppressive CD4+ cells. The gene discussed is CD8A; the disease is neoplasm.